Takeda and Roivant launch Myovant Sciences Ltd
7 June 2016 | By Victoria White, Digital Content Producer
Myovant Sciences is a biopharmaceutical company focused on delivering innovative women’s health and prostate cancer therapeutics...
List view / Grid view
7 June 2016 | By Victoria White, Digital Content Producer
Myovant Sciences is a biopharmaceutical company focused on delivering innovative women’s health and prostate cancer therapeutics...
3 June 2016 | By Victoria White, Digital Content Producer
The Phase III study ARASENS will evaluate BAY-1841788 in men with newly diagnosed metastatic hormone-sensitive prostate cancer...
25 May 2016 | By Victoria White, Digital Content Producer
Jevtana has been recommended in combination with other drugs as a treatment option for metastatic hormone-relapsed prostate cancer in England...
22 April 2016 | By Victoria White, Digital Content Producer
NICE has issued final guidance recommending Sanofi’s Jevtana (cabazitaxel) for some prostate cancer patients...
8 April 2016 | By Victoria White, Digital Content Producer
Tesaro will receive an upfront payment of $35 million, and is eligible to receive additional milestone payments of up to $415 million...